Invo Bioscience Inc is a biotechnology company focused on developing innovative solutions for reproductive health, particularly in the field of assisted reproductive technology
Their flagship product offers a unique, minimally invasive approach to treating infertility by providing a platform that enhances the success rates of in vitro fertilization (IVF) procedures. The company's goal is to increase accessibility and affordability of reproductive care, making it easier for individuals and couples facing challenges with fertility to achieve their dreams of parenthood. Through ongoing research and development, Invo Bioscience aims to improve outcomes for patients while simplifying the overall IVF process.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The S&P 500 also fell, dropping, 0.74% to 5,013.98.
Invo Bioscience reported $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year. The company also said it remains on-track with its goal of reaching break-even or profitability within its current operations in 2024.
